¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå
Orthobiologics
»óǰÄÚµå : 1765141
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 193 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ¼¼°è ½ÃÀåÀº 2030³â±îÁö 90¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 71¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ¼¼°è ½ÃÀåÀº 2024-2030³â CAGR 4.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 90¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °üÀý³» º¸Ãæ ¿ä¹ýÀº CAGR 5.1%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 41¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇÕ¼º ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 3.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 19¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 3.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀåÀº 2024³â¿¡ 19¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 14¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 3.8%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.9%¿Í 3.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.1%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º¶õ ¹«¾ùÀ̸ç, ¿Ö Á¤Çü¿Ü°ú ÀÇ·á¿¡¼­ Áß¿äÇѰ¡?

Á¤Çü¿Ü°ú ½Ã¼ú¿¡¼­ »À, ±ÙÀ°, ÈûÁÙ, ÀδëÀÇ Ä¡À¯¸¦ ÃËÁøÇϱâ À§ÇØ »ç¿ëµÇ´Â »ý¹°ÇÐÀû À¯·¡ ¹°ÁúÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹°Áú¿¡´Â ´ÙÇ÷¼ÒÆÇ Ç÷Àå(PRP), »À ÀÌ½ÄÆí, Áٱ⼼Æ÷, È÷¾Ë·ç·Ð»ê µîÀÌ Æ÷ÇԵǸç, ¿°ÁõÀ» ¾ïÁ¦Çϰí Á¶Á÷ Àç»ýÀ» ÃËÁøÇϸç ȸº¹À» °¡¼ÓÈ­ÇÏ¿© ½ÅüÀÇ ÀÚ¿¬ Ä¡À¯ °úÁ¤À» °³¼±Çϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º´Â ½ºÆ÷Ã÷ ¿Ü»ó, ÅðÇ༺ °üÀý Áúȯ, ôÃß ÁúȯÀÇ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ȯÀÚ¿¡°Ô ¼ö¼ú¿¡ ´ëÇÑ ÃÖ¼Ò Ä§½ÀÀû ´ë¾ÈÀ» Á¦°øÇϰųª °æ¿ì¿¡ µû¶ó¼­´Â º¸Á¶ ¿ä¹ýÀ¸·Î »ç¿ëµÇ¾î ¼ö¼ú °á°ú¸¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ½ÅüÀÇ ÀÚ¿¬Àû Àç»ý ´É·ÂÀ» Ȱ¿ëÇÔÀ¸·Î½á ±Ù°ñ°Ý°è Ä¡·áÀÇ À¯¸ÁÇÑ ¹ßÀüÀÎ Á¤À§»ý¹°ÇÐÀº ´õ ºü¸¥ Ä¡À¯¸¦ °¡Á®¿À°í ±âÁ¸ Ä¡·á¿Í °ü·ÃµÈ ÇÕº´ÁõÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¼ö¼ú ÀÌ¿ÜÀÇ Ä¡·á¹ýÀ» ã´Â ȯÀÚ Áõ°¡¿Í Á¤Çü¿Ü°ú ¼ö¼ú¿¡¼­ »ý¹°ÇÐÀû Á¦Á¦°¡ ºÎ»óÇϰí ÀÖ´Â °ÍÀÌ ±× äÅÃÀÌ È®´ëµÇ°í ÀÖ´Â ¹è°æÀÔ´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô ¿À¸£¼Ò¹ÙÀÌ¿À·ÎÁ÷½º »ê¾÷À» Çü¼ºÇϰí Àִ°¡?

±â¼ú Çõ½ÅÀº ƯÈ÷ Àç»ýÀÇ·á¿Í Á¶Á÷°øÇÐ ºÐ¾ß¿¡¼­ ¿À¸£¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀåÀ» ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. Áٱ⼼Æ÷ ¿¬±¸ÀÇ ¹ßÀüÀº Àç»ý Ä¡·áÀÇ °¡´É¼ºÀ» ³ÐÇû°í, Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·á´Â Á¤Çü¿Ü°ú ȯÀÚÀÇ ¿¬°ñ, »À, ¿¬ºÎÁ¶Á÷ÀÇ ¼öº¹¿¡ À¯¸ÁÇÑ Ä¡·á¹ýÀ¸·Î ¿©°ÜÁö°í ÀÖ½À´Ï´Ù. Ç÷¼ÒÆÇÀÌ ³óÃàµÈ Ç÷¼ÒÆÇÀ» ¼Õ»óµÈ Á¶Á÷¿¡ ÁÖÀÔÇÏ¿© Ä¡À¯¸¦ ÃËÁøÇÏ´Â Ç÷¼ÒÆÇÀÌ Ç³ºÎÇÑ Ç÷Àå(PRP) ¿ä¹ýÀÇ °³¼±µµ ´Ù¾çÇÑ ±Ù°ñ°Ý°è ¼Õ»ó¿¡ ´ëÇÑ ºñ¼ö¼úÀû Ä¡·áÀÇ È¿°ú¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, õ¿¬ »ÀÀÇ Æ¯¼ºÀ» ¸ð¹æÇÑ ÇÕ¼º »À À̽ÄÀÇ °³¹ß·Î Á¤Çü¿Ü°ú ÀÇ»çµéÀº ôÃß °íÁ¤¼ú ¹× ¿Ü»ó ȯÀÚ¿¡¼­ »À Àç»ýÀ» À§ÇÑ ¼±ÅÃÀÇ ÆøÀÌ ³Ð¾îÁ³½À´Ï´Ù. ¶ÇÇÑ, ºñ°è ¹× ÇÏÀ̵å·Î°Ö »ç¿ë°ú °°Àº ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º Àü´Þ ½Ã½ºÅÛÀÇ Çõ½ÅÀº ÀÌ·¯ÇÑ Ä¡·áÀÇ Á¤È®¼º°ú È¿´ÉÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû Áøº¸·Î ÀÎÇØ Á¤Çü»ýü°øÇÐÀÇ Àû¿ë ¹üÀ§°¡ ³Ð¾îÁö°í, °üÀýÀÇ ¼öº¹¿¡¼­ ôÃßÀÇ º¯Çü¿¡ À̸£±â±îÁö º¸´Ù ±¤¹üÀ§ÇÑ Áõ»ó¿¡ Àû¿ëµÉ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¿À¸£¼Ò¹ÙÀÌ¿À·ÎÁ÷½º´Â ¾îµð¿¡¼­ °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â°¡?

Á¤Çü¿Ü°ú, ½ºÆ÷Ã÷ÀÇÇÐ, ¿Ü»óÄ¡·á¿¡ ÁÖ·Î »ç¿ëµÇ¸ç, ôÃß °íÁ¤¼ú, °üÀý ¼öº¹, ¿¬ºÎÁ¶Á÷ Àç»ý¿¡ ´ëÇÑ ÀÀ¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ºÆ÷Ã÷ ÀÇÇп¡¼­ PRP¿Í Áٱ⼼Æ÷ Ä¡·á´Â °Ç¿°, ÀÎ´ë ÆÄ¿­, ¿¬°ñ ¼Õ»ó µîÀÇ ºÎ»ó Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ¾î ¿îµ¿¼±¼öÀÇ Á¶±â ȸº¹°ú ¼ö¼ú ȸÇÇ¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. Á¤Çü¿Ü°ú¿¡¼­´Â ôÃß °íÁ¤¼ú°ú °°ÀÌ »ÀÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ôÃ߸¦ ¾ÈÁ¤È­½Ã۱â À§ÇØ »À À̽ÄÀ̳ª ´ëü »À°¡ ÇÊ¿äÇÑ ½Ã¼ú¿¡ ¿À¸£¼Ò¹ÙÀÌ¿À·ÎÁ÷½º°¡ ÀÚÁÖ »ç¿ëµË´Ï´Ù. ƯÈ÷ ¹«¸­À̳ª ¾î±ú °üÀý Àç°Ç¼úÀº Á¶Á÷ ȸº¹À» ÃËÁøÇϰí ȸº¹ ½Ã°£À» ´ÜÃàÇϱâ À§ÇØ Á¤À§»ý¹°ÇÐÀÌ ÀÚÁÖ »ç¿ëµÇ´Â ºÐ¾ßÀÔ´Ï´Ù. ¶ÇÇÑ, ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º´Â °ñ°üÀý¿°°ú °°Àº ÅðÇ༺ °üÀý ÁúȯÀÇ Ä¡·á¿¡µµ »ç¿ëµÇ¾î ÅëÁõ ¿ÏÈ­ ¹× °üÀý ±â´É ȸº¹¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿Ü»ó Ä¡·á¿¡µµ »ç¿ëÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ƯÈ÷ °ñÀ¯ÇÕ ÃËÁøÀÌ ÇÊ¿äÇÑ º¹ÀâÇÑ °ñÀý¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

¿À¸£¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀåÀÇ ¼ºÀåÀº ±Ù°ñ°Ý°è ÁúȯÀÇ À¯º´·ü Áõ°¡, ÃÖ¼Òħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Àç»ýÀÇ·áÀÇ ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ¼¼°è Àα¸ÀÇ °í·ÉÈ­À̸ç, ÀÌ·Î ÀÎÇØ °ñ°üÀý¿°, °ñ´Ù°øÁõ°ú °°Àº Á¤Çü¿Ü°ú ÁúȯÀÇ À¯º´·üÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, ¸ðµÎ Á¤Çü¿Ü°úÀû »ý¹°ÇÐÀû Ä¡·á°¡ È¿°úÀûÀÔ´Ï´Ù. Àúħ½ÀÀûÀÌ°í ºñ¼ö¼úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù. Áٱ⼼Æ÷ Ä¡·á, ´ÙÇ÷¼ÒÆÇ Ç÷Àå(PRP), »À ÀÌ½Ä ´ëü¹° µîÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½ºÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â ÁúȯÀÇ ¹üÀ§°¡ ´õ¿í ³Ð¾îÁö°í, ´õ È¿°úÀûÀÌ°í ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÃÖ÷´Ü Ä¡·á¸¦ ¿øÇÏ´Â ÇÁ·Î ¿îµ¿¼±¼ö¿Í Ȱµ¿ÀûÀÎ »ç¶÷µéÀÌ ½ºÆ÷Ã÷ ÀÇÇп¡¼­ Á¤À§»ý¹°ÇÐÀ» Á¡Á¡ ´õ ¸¹ÀÌ Ã¤ÅÃÇϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, Á¤Çü¿Ü°ú ÀÇ·á¿¡¼­ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÌ ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ßÀº ÀÓ»ó ¹× ¼ö¼ú Àå¸é ¸ðµÎ¿¡¼­ ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ ±¤¹üÀ§ÇÑ »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(°üÀý³» º¸Ãæ ¿ä¹ý, ÇÕ¼º ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º, DBM, BMP, ±âŸ Á¦Ç°);¿ëµµ(°ñ°üÀý¿° ¹× ÅðÇ༺ °üÀý¿°, °ñÀý ȸº¹, ôÃß °íÁ¤, ¿¬ºÎ Á¶Á÷ ¼Õ»ó, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Orthobiologics Market to Reach US$9.0 Billion by 2030

The global market for Orthobiologics estimated at US$7.1 Billion in the year 2024, is expected to reach US$9.0 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Viscosupplementation, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Synthetic Orthobiologics segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 3.8% CAGR

The Orthobiologics market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 3.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Orthobiologics Market - Key Trends & Drivers Summarized

What Are Orthobiologics, and Why Are They Critical in Orthopedic Medicine?

Orthobiologics are biologically derived substances used to enhance the healing of bones, muscles, tendons, and ligaments in orthopedic procedures. These substances, which include platelet-rich plasma (PRP), bone grafts, stem cells, and hyaluronic acid, are designed to improve the body’s natural healing processes by reducing inflammation, promoting tissue regeneration, and accelerating recovery. Orthobiologics are widely used in treatments for sports injuries, degenerative joint diseases, and spinal conditions, offering patients a minimally invasive option to surgery or, in some cases, improving surgical outcomes when used as an adjunct therapy. By leveraging the body’s natural regenerative capacity, orthobiologics represent a promising advancement in musculoskeletal care, providing faster healing and reducing complications associated with traditional treatments. Their growing adoption is being driven by increased patient demand for non-surgical treatment options and the rise of biologics in orthopedic surgery.

How Are Technological Advancements Shaping the Orthobiologics Industry?

Technological innovations are propelling the orthobiologics market forward, particularly in the areas of regenerative medicine and tissue engineering. Advances in stem cell research have expanded the possibilities for regenerative treatments, with stem cell-based therapies showing promise in repairing cartilage, bone, and soft tissues in orthopedic patients. The refinement of platelet-rich plasma (PRP) therapies, where concentrated platelets are injected into damaged tissue to promote healing, has also increased the effectiveness of non-surgical treatments for a variety of musculoskeletal injuries. Furthermore, developments in synthetic bone graft substitutes, which mimic the properties of natural bone, are offering orthopedic surgeons more options for bone regeneration in spinal fusion and trauma cases. Additionally, innovations in the delivery systems for orthobiologics, such as the use of scaffolds or hydrogels, are improving the precision and efficacy of these therapies. These technological advancements are enhancing the scope of orthobiologics, making them more versatile and applicable to a wider range of conditions, from joint repair to spinal deformities.

Where Are Orthobiologics Being Used Most Extensively?

Orthobiologics are primarily used in orthopedic surgeries, sports medicine, and trauma care, with increasing applications in spinal fusion, joint repair, and soft tissue regeneration. In sports medicine, PRP and stem cell therapies are widely used to treat injuries such as tendonitis, ligament tears, and cartilage damage, helping athletes recover faster and avoid surgery. In orthopedic surgery, orthobiologics are frequently used in procedures like spinal fusion, where bone grafts or bone substitutes are needed to promote bone growth and stabilize the spine. Joint reconstruction, particularly in the knee and shoulder, is another area where orthobiologics are commonly employed to enhance tissue repair and reduce recovery times. Moreover, orthobiologics are gaining traction in treating degenerative joint diseases such as osteoarthritis, where they help alleviate pain and restore joint function. Their use in trauma care is also expanding, particularly for complex fractures that require enhanced bone healing.

What Is Driving the Growth of the Orthobiologics Market?

The growth in the orthobiologics market is driven by several factors, including the rising prevalence of musculoskeletal disorders, an increasing demand for minimally invasive procedures, and advancements in regenerative medicine. One of the primary drivers is the aging global population, which is leading to a higher incidence of orthopedic conditions such as osteoarthritis and osteoporosis, both of which benefit from orthobiologic treatments. The growing demand for minimally invasive and non-surgical treatment options is another significant driver, as patients increasingly seek alternatives to traditional surgery for faster recovery and fewer complications. Technological advancements in stem cell therapies, platelet-rich plasma (PRP), and bone graft substitutes are further expanding the range of conditions that can be treated with orthobiologics, making them more effective and accessible. Additionally, the increasing adoption of orthobiologics in sports medicine, driven by professional athletes and active individuals looking for cutting-edge treatments, is contributing to market growth. Lastly, the rising awareness of the benefits of biologics in orthopedic care, coupled with ongoing research and development in the field, is driving the broader use of these therapies in both clinical and surgical settings.

SCOPE OF STUDY:

The report analyzes the Orthobiologics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Viscosupplementation, Synthetic Orthobiologics, DBM, BMP, Other Products); Application (Osteoarthritis & Degenerative Arthritis, Fracture Recovery, Spinal Fusion, Soft Tissue Injuries, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â